

Confirmation No.

PTQ/SB/O&amp;A (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substituted for form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

**Complete if Known**

Application Number

Filing Date

First Named Inventor

Kazuo Ando, et al.

---

**Art Unit**

Examiner Name \_\_\_\_\_

Attorney Docket Number

PC26145A

## U. S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cita No.1	FOREIGN PATENT DOCUMENT		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	†*
		Country Code* Number † Kind Code* (if known)					
/CC/		WO1996/06081 A1		02-29-1996	Pfizer Inc		
/CC/		WO 1997/23216 A1		07-03-1997	Warner-Lambert Co.		
/CC/		WO 1999/21539 A1		05-06-0199	Warner-Lambert Co.		

Examiner Signature	/Celia Chang/	Date Considered	12/10/2008
-----------------------	---------------	--------------------	------------

\*EXAMINER: indicate if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*Applicant's unique citation designation number (optional). \*See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. \*Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \*For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \*Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. \*Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

EXPRESS MAIL NO. EV545394292US  
DOCKET NO. PC26145A

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449PTO		Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		Application Number	10/575383
		Filing Date	
		First Named Inventor	Kazuo Ando, et al.
		Art Unit	
		Examiner Name	
Sheet 2 of 3	Attorney Docket Number	PC26145A	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/CC/		S. BOYCE, et al., "Selective NMDA NR2B antagonists induce antinociception without motor dysfunction: correlation with restricted localisation of NR2B subunit in dorsal horn" <i>Neurpharmacology</i> , 199, pp 611-623, Vol. 38, No. 5	
		I CAVERO, et al., "Drugs that prolong QT interval as an unwanted effect: assessing their likelihood of inducing hazardous cardiac dysrhythmias", <i>Expert Opinion on Pharmacotherapy</i> , 2000, pp 947-973, Vol. 1, No. 5	
		K. FINLAYSON, et al., "[3H]Dofetilide binding to HERG transfected membranes: a potential high throughput preclinical screen", <i>Euro J Pharmacology</i> , 2001, pp 147-148, Vol. 430, No. 1	
		D. M. GRENNAN, et al., "Rheumatoid Arthritis", <i>Textbook of Pain</i> , 1994, pp 397-407	
		J. H. HOGUE, et al., "Pathophysiology and First-Line Treatment of Osteoarthritis", <i>The Annals of Pharmacotherapy</i> , 2002, pp 679-686, Vol. 36	
		J. LEVINE, et al., "Inflammatory Pain", <i>Textbook of Pain</i> , 1994, pp 45-56	
		C. MCCARTHY, et al., "Osteoarthritis", <i>Textbook of Pain</i> , 1994, pp 387-396	
		R. A. MEYER, et al., "Peripheral Neural Mechanisms of Nociception", <i>Textbook of Pain</i> , 1994, pp 13-55	
		M. J. MILLAN, et al., "The Induction of Pain: An Integrative Review", <i>Progress in Neurobiology</i> , 1999, pp 1-64, Vol. 57	
/CC/		C. J. WOOLF, et al., "Implications of Recent Advances in the Understanding of Pain Pathophysiology for the Assessment of Pain in Patients", <i>Pain Supplement</i> , 1999, pp S141-S147, No. 6	

Examiner Signature	/Celia Chang/	Date Considered	12/10/2008
--------------------	---------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Approved for use through 07/31/2006. OMB 0651-0031  
Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**Complete if Known**

(Use as many sheets as necessary)

Filing Date

**First Named Inventor**

Art Unit

Examiner Name \_\_\_\_\_

Attorney Docket Number

10/575383
-----------

Kazuo Ando, et al.

PC26145A

Sheet

3

of

3

Examiner  
Initials\*Cite  
No.<sup>1</sup>

Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.

 $T^2$ 

/CC/

C. J. WOOLF, et al., "Neuronal Plasticity: Increasing the Gain in Pain", *Science*, 2000, pp 1765-1768, Vol. 288

/CC/

C. J. WOOLF, et al., "Neuropathic pain: aetiology, symptoms, mechanisms, and management", *The Lancet*, 1999, pp 1959-1964, Vol. 353, No. 9168

Examiner  
Signature

/Celia Chang/

Date \_\_\_\_\_

Considered

12/10/2008

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.959. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

*If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.*